Author(s): I Ketut Mariadi, Ni Nyoman Metriani Nesa, Gde Somayana, Kurniawan

Email(s): mariadi@unud.ac.id

DOI: 10.52711/0974-360X.2024.00163   

Address: I Ketut Mariadi1, Ni Nyoman Metriani Nesa2, Gde Somayana1, Kurniawan3
1Gastroentero-hepatology Division, Department of Internal Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Indonesia.
2Gastroentero-hepatology Division, Department of Pediatric, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Indonesia.
3Department of Internal Medicine, Udayana University/Prof. Dr. I.G.N.G. Ngoerah General Hospital, Indonesia.
*Corresponding Author

Published In:   Volume - 17,      Issue - 3,     Year - 2024


ABSTRACT:
Colorectal cancer is one of the most common cancers, causing mortality, morbidity, and economic burden. Patient survival differs due to differences in access to health facilities, as well as diagnostic and therapeutic modalities. Early detection can allow colorectal cancer to be diagnosed at an earlier stage, improving patient outcomes and lowering mortality. Due to the lack of a national screening program in Indonesia, as well as the uneven availability of colonoscopy tools, the fecal immunochemical test has become the preferred screening method. This cross-sectional study aims to validate the application of the fecal immunochemical test for colorectal cancer detection. Fecal immunochemical test examination is performed on all patients with suspected colorectal cancer who will undergo a colonoscopy examination at Prof. Hospital dr. I.G.N.G. Ngoerah, Bali, Indonesia. Histopathological examination is used to diagnose colorectal cancer. This study included 78 people with a colorectal cancer prevalence of 40.91%. There were 38(57.6%) subjects with positive fecal immunochemical test results in this study, and 25(65.6%) of them were diagnosed with colorectal cancer. The sensitivity, specificity, positive predictive value, and negative predictive value of the qualitative fecal immunochemical test in detecting colorectal cancer were 92.59%, 66.67%, 65.79%, and 92.86%, respectively. The qualitative fecal immunochemical test has high sensitivity and can be used as an objective and accurate method of screening symptomatic patients with suspected CRC for colonoscopy.


Cite this article:
I Ketut Mariadi, Ni Nyoman Metriani Nesa, Gde Somayana, Kurniawan. Qualitative Fecal Immunochemical Test as a Screening Test for Colorectal Cancer. Research Journal of Pharmacy and Technology. 2024; 17(3):1050-4. doi: 10.52711/0974-360X.2024.00163

Cite(Electronic):
I Ketut Mariadi, Ni Nyoman Metriani Nesa, Gde Somayana, Kurniawan. Qualitative Fecal Immunochemical Test as a Screening Test for Colorectal Cancer. Research Journal of Pharmacy and Technology. 2024; 17(3):1050-4. doi: 10.52711/0974-360X.2024.00163   Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-3-14


REFERENCES:
1.    Bray F. Ferlay J. Soerjomataram I. Siegel RL. Torre LA. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. doi: 10.3322/caac.21492.
2.    Global Burden of Disease Cancer Collaboration; Fitzmaurice C. Abate D. Abbasi N. Abbastabar H. Abd-Allah F. Abdel-Rahman O. Abdelalim A et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019; 5(12):1749-1768. doi: 10.1001/jamaoncol.2019.2996.
3.    Wong MC. Ding H. Wang J. Chan PS. Huang J. Prevalence and risk factors of colorectal cancer in Asia. Intest Res. 2019; 17(3): 317-329. doi: 10.5217/ir.2019.00021.
4.    Dwiputra Y. Mariadi I. Prathiwi P. Somayana G. Suryadarma IGA. Purwadi N. Wibawa IDN. Profil Penderita Kanker Kolorektal RSUP Sanglah Denpasar Periode 2010-2014. Available at: https://simdos.unud.ac.id/uploads/file_penelitian_1_dir/c80ace527dde9722c4b44a0450c3c4d3.pdf.
5.    Schreuders EH. Ruco A. Rabeneck L. Schoen RE. Sung JJ. Young GP. Kuipers EJ. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10): 1637-49. doi: 10.1136/gutjnl-2014-309086.
6.    Araghi M. Arnold M. Rutherford MJ. Guren MG. Cabasag CJ. Bardot A. Ferlay J et al. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project). Gut. 2021; 70(1):114-126. doi: 10.1136/gutjnl-2020-320625.
7.    Onyoh EF. Hsu WF. Chang LC. Lee YC. Wu MS. Chiu HM. The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management. Curr Gastroenterol Rep. 2019; 21(8): 36. doi: 10.1007/s11894-019-0703-8.
8.    Sung JJ. Ng SC. Chan FK. Chiu HM. Kim HS. Matsuda T. Ng SS. et al; Asia Pacific Working Group. An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut. 2015; 64(1):121-32. doi: 10.1136/gutjnl-2013-306503.
9.    Abdullah M. Sudoyo AW. Utomo AR. Fauzi A. Rani AA. Molecular profile of colorectal cancer in Indonesia: is there another pathway? Gastroenterol Hepatol Bed Bench. 2012; 5(2):71-8. PMID: 24834203; PMCID: PMC4017456.
10.    Bailey CE. Hu CY. You YN. Bednarski BK. Rodriguez-Bigas MA. Skibber JM. Cantor SB et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015; 150(1):17-22. doi: 10.1001/jamasurg.2014.1756.
11.    Zorzi M. Fedeli U. Schievano E. Bovo E. Guzzinati S. Baracco S. Fedato C. et al. Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test. Gut. 2015; 64(5):784-90. doi: 10.1136/gutjnl-2014-307508.
12.    Luther J. Chan A. Malignant tumors of the colon. In: Podolsky D, Camilleri M, Fitz J et al. (eds). Yamada’s Textbook of Gastroenterology. John Wiley & Sons Ltd: West Sussex, 2016, pp 1554–1607.
13.    Joy JM. Antony RJ. Rajagopal SS. Dietary fiber intake and benefit of colorectal cancer. Asian J. Res. Pharm. Sci. 2019; 9(3):209-114. doi: 10.5958/2231-5659.2019.00033.X.
14.    Zam W. Dawod R. Overview of the Probiotics’ role in Gastrointestinal disorders. Research J. Pharm. and Tech. 2020; 13(11):5557-5561. doi: 10.5958/0974-360X.2020.00970.1.
15.    Inada R. Nagasaka T. Watanabe A. Yagi T. Mori Y. Kondo Y. Kishimoto H et al. Comparison of outcomes between symptomatic and asymptomatic patients with colorectal cancer: a propensity score-matched analysis of surgical invasiveness, medical costs and oncological outcomes. BMJ Open Gastroenterol. 2017; 4(1):e000146. doi: 10.1136/bmjgast-2017-000146.
16.    Vega P. Valentín F. Cubiella J. Colorectal cancer diagnosis: Pitfalls and opportunities. World J Gastrointest Oncol. 2015 Dec 15; 7(12):422-33. doi: 10.4251/wjgo.v7.i12.422.
17.    Walter FM. Emery JD. Mendonca S. Hall N. Morris HC. Mills K. Dobson C. et al. Symptoms and patient factors associated with longer time to diagnosis for colorectal cancer: results from a prospective cohort study. Br J Cancer. 2016; 115(5):533-41. doi: 10.1038/bjc.2016.221.
18.    Deshmukh R. Kumari S. Harwansh RK. Inflammatory Bowel Disease: A Snapshot of Current Knowledge. Research J. Pharm. and Tech. 2020; 13(2): 956-962. doi: 10.5958/0974-360X.2020.00180.8.
19.    Astin M. Griffin T. Neal RD. Rose P. Hamilton W. The diagnostic value of symptoms for colorectal cancer in primary care: a systematic review. Br J Gen Pract. 2011; 61(586):e231-43. doi: 10.3399/bjgp11X572427.
20.    National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. NICE: London, 2017.
21.    Westwood M. Lang S. Armstrong N. van Turenhout S. Cubiella J. Stirk L. Ramos IC et al. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med. 2017; 15(1):189. doi: 10.1186/s12916-017-0944-z.
22.    Rodríguez-Alonso L. Rodríguez-Moranta F. Ruiz-Cerulla A. Lobatón T. Arajol C. Binefa G. Moreno V et al. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test. Dig Liver Dis. 2015; 47(9):797-804. doi: 10.1016/j.dld.2015.05.004.
23.    Sachdeo RA. Charde MS. Chakole RD. Colorectal cancer: an overview. Asian J. Res. Pharm. Sci. 2020; 10(3):211-23. doi: 10.5958/2231-5659.2020.00040.5.
24.    Du VV. Lam ND. Tung DV. Valuating concentration of Cea, Ca 19-9 and some biochemical parameters in patients with colorectal cancer. Int. J. of Advances in Nur. Management. 2018; 6(2): 93-7. doi: 10.5958/2454-2652.2018.00020.3.
25.    Mathew KS. Thomas A. Roshni PR, Sivadas A. Pavithran K. Clinical evidence of regorifenib in metastatic colorectal cancer: a case report. Research J. Pharm. and Tech. 2019; 12(2):513-515. doi: 10.5958/0974-360X.2019.00090.8.
26.    Pandey AN. Raj R. Ganesh N. Jain SK. Concanavalin-A conjugated 5-fluorouracil loaded PLGA nanoparticles: a novel approach for effective treatment of colorectal cancer. Research J. Pharm. and Tech. 2018; 11(7): 2782-91. doi: 10.5958/0974-360X.2018.00514.0.
27.    Kumbhar DM. Mali KK. Dias RJ. Havaldar VD. Ghorpade VS. Salunkhe NH. Formulation and development of ethyl cellulose coated pectin based capecitabine loaded microspheres for colorectal cancer. Res. J. Pharm. Dosage Form. & Tech. 2016; 8(4): 261-8. doi: 10.5958/0975-4377.2016.00036.7.
28.    Wiyarta E. Kusmardi K. Midoen YH. Effect of omega-3-rich fish oil on TNF- α expression in mice's colonic tissue induced with azoxymethane (AOM) and dextran sodium sulphate (DSS). Research Journal of Pharmacy and Technology. 2022; 15(7):3179-4. doi: 10.52711/0974-360X.2022.00532.
29.    Barua CC. Barbhuiya SAA. Kakati A, Buragohain L. Syamprasad Np. Gawali B. Naidu V. Methanolic extract of Entada phaseoloides inhibits colorectal carcinoma cells proliferation of HT-29 cell by modulating mitochondria-mediated apoptotic pathway. Research Journal of Pharmacy and Technology. 2022; 15(10):4439-6. doi: 10.52711/0974-360X.2022.00744.
30.    Elkhateeb WA. Mohamed MA. Fayad W. Emam M. Nafady IM. Daba GM. Molecular identification, metabolites profiling, anti-breast cancer, anti-colorectal cancer, and antioxidant potentials of Streptomyces zaomyceticus AA1 isolated from a remote bat cave in Egypt. Research J. Pharm. and Tech. 2020; 13(7): 3072-3080. doi: 10.5958/0974-360X.2020.00545.4.


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available